Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













User:Mr. Ibrahem/Cryoprecipitate

















●User page
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●User contributions
 ●User logs
 ●View user groups
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Get shortened URL
 ●Download QR code
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  
< User:Mr. Ibrahem
Mr. Ibrahem/Cryoprecipitate
Clinical data
Other namesCryo, cryoprecipitated antihaemophilic factor, cryoprecipitated AHF
Drug classBlood product[1]

Cryoprecipitate, also called cryo, is a blood product made from blood plasma.[1] Uses include blood clotting problems, such as obstetrical bleedingorDIC, due to low fibrinogen; and congenital afibrinogenemia.[2][3][1] While it has be used for hemophilia Aorvon Willebrand disease, more specific clotting factor concentrates are preferred.[4] It is given by injection into a vein.[5] Cross-matching (compatibility testing) is not required, though matching the ABO groups is preferred if possible.[4] It is often given to adults as two 5-unit pools.[4][3]

Side effects may include fever, allergic reactions, acute hemolytic reaction, TRALI, and infections.[4] It should generally not be used in urinary tract bleeding.[1] It is made by thawing fresh frozen plasma at 4 °C then centrifuging and collecting the precipitate.[1][4] This is then resuspended in a small amount of residual plasma (generally 15 to 30 mL) and is re-frozen for storage.[4][3] It contains factor VIII, von Willebrand factor (VWF), fibrinogen, fibronectin, and factor XIII.[3]

Cryoprecipitate was developed in 1964 by Judith Pool.[6][7] It was the first treatment for hemophilia A.[1] It is on the World Health Organization's List of Essential Medicines.[5] It can be stored at -25 °C for up to a year and a half.[3] After thawing and at room temperature it should be used within 4 hours.[3] It costs the NHS about £181 in the United Kingdom for a 5 unit pooled dose of cryoprecipitate.[3] It is less expensive then fibrinogen concentrate.[4]

References[edit]

  1. ^ a b c d e f g Fung MK, Grossman BJ, Hillyer CD, Westhoff CM (2014). Technical manual (18th ed.). Bethesda, Md.: American Association of Blood Banks. p. 523. ISBN 978-1563958885. OCLC 881812415.
  • ^ a b "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 20 October 2023. Retrieved 25 September 2023.
  • ^ a b c d e f g h i Centre (UK), National Clinical Guideline (November 2015). "Cryoprecipitate: thresholds and targets". Blood Transfusion. National Institute for Health and Care Excellence (NICE). Archived from the original on 2023-12-04. Retrieved 2023-12-02.
  • ^ a b c d e f g h i Pearlman, James; Nickson, Chris; Nickson, James Pearlman and Chris (30 January 2019). "Cryoprecipitate". Life in the Fast Lane • LITFL. Archived from the original on 5 June 2023. Retrieved 2 December 2023.
  • ^ a b World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  • ^ Ross, Stewart (15 September 2020). Who Invented Underpants?: The Weird Trivia of Human Invention, from Fire to Fast Food (and Everything In Between). Simon and Schuster. p. 86. ISBN 978-1-64604-097-1.
  • ^ Shapiro, Frederic (20 December 2015). Pediatric Orthopedic Deformities, Volume 1: Pathobiology and Treatment of Dysplasias, Physeal Fractures, Length Discrepancies, and Epiphyseal and Joint Disorders. Springer. p. 479. ISBN 978-3-319-20529-8. Archived from the original on 4 December 2023. Retrieved 2 December 2023.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Cryoprecipitate&oldid=1198154238"
    Hidden category: 
    ●Pages using duplicate arguments in template calls
      


    ●This page was last edited on 23 January 2024, at 05:17 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki